Patterns of care for early stage bladder cancer

Early stage bladder cancer is a heterogeneous disease with a variable risk of progression and mortality. Uncertainty surrounding the optimal care for these patients may result in a mismatch between disease risk and treatment intensity.

[1]  J. Birkmeyer,et al.  Provider treatment intensity and outcomes for patients with early-stage bladder cancer. , 2009, Journal of the National Cancer Institute.

[2]  Sanjay Kaul,et al.  The disconnect between practice guidelines and clinical practice--stressed out. , 2008, JAMA.

[3]  T. Cai,et al.  Is There an Optimal Comorbidity Index for Prostate Cancer? , 2008, Cancer.

[4]  M. Babjuk,et al.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. , 2008, European urology.

[5]  Martin Schumacher,et al.  Evidence from nonrandomized studies: a case study on the estimation of causal effects. , 2008, American journal of epidemiology.

[6]  P. Schellhammer,et al.  Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. , 2007, The Journal of urology.

[7]  R. Dunn,et al.  Early-stage bladder cancer surveillance does not improve survival if high-risk patients are permitted to progress to muscle invasion. , 2007, Urology.

[8]  D. Lubeck,et al.  Assessment of prognosis with the total illness burden index for prostate cancer , 2007, Cancer.

[9]  J Alfred Witjes,et al.  Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. , 2006, European urology.

[10]  Karla Lindquist,et al.  Development and validation of a prognostic index for 4-year mortality in older adults. , 2006, JAMA.

[11]  M. Soloway.  Re: Schrier BPh, Hollander MP, van Rhijn BWG, Kiemeney LALM, Witjes JA. Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol 2004;45:292-6. , 2005, European urology.

[12]  R. Sylvester,et al.  A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. , 2004, The Journal of urology.

[13]  L. Kiemeney,et al.  Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. , 2004, European urology.

[14]  Nicholas J Vogelzang,et al.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. , 2003, The New England journal of medicine.

[15]  Hargraves Jl,et al.  Seeking health care information: most consumers still on the sidelines. , 2003 .

[16]  Ruth Etzioni,et al.  Estimating Health Care Costs Related to Cancer Treatment From SEER-Medicare Data , 2002, Medical care.

[17]  Deborah Schrag,et al.  Overview of the SEER-Medicare Data: Content, Research Applications, and Generalizability to the United States Elderly Population , 2002, Medical care.

[18]  L. Chambless,et al.  Neighborhood of residence and incidence of coronary heart disease. , 2001, The New England journal of medicine.

[19]  M. Marmot,et al.  Inequalities in Health , 2014 .

[20]  S. Groshen,et al.  Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J L Warren,et al.  Development of a comorbidity index using physician claims data. , 2000, Journal of clinical epidemiology.

[22]  D. Lamm,et al.  Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. , 2000, The Journal of urology.

[23]  James M. Kozlowski,et al.  NCCN Urothelial Cancer Practice Guidelines , 1998 .

[24]  C. Pashos,et al.  The health economics of bladder cancer , 2012, PharmacoEconomics.

[25]  C. Sternberg,et al.  Optimizing outcomes at every stage of bladder cancer: do we practice it? , 2009, Urologic oncology.

[26]  Alberto Redaelli,et al.  The health economics of bladder cancer: a comprehensive review of the published literature. , 2003, PharmacoEconomics.

[27]  Ha T Tu,et al.  Seeking health care information: most consumers still on the sidelines. , 2003, Issue brief.

[28]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[29]  H. Herr,et al.  Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome. , 2000, The Journal of urology.

[30]  A Pollack,et al.  NCCN urothelial cancer practice guidelines. National Comprehensive Cancer Network. , 1998, Oncology.

[31]  H. Genster,et al.  Prolonging follow-up intervals for non-invasive bladder tumors: a randomized controlled trial. , 1995, Scandinavian journal of urology and nephrology. Supplementum.